Literature DB >> 24825327

Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort.

Karin Elebro1, Salma Butt, Mozhgan Dorkhan, Helena Jernström, Signe Borgquist.   

Abstract

PURPOSE: Risk factors for breast cancer vary according to breast cancer subtype. This study analyzes the impact of potential risk factors in breast cancer by androgen receptor (AR) status.
METHODS: A total of 17,035 women were followed in the population-based prospective Malmö Diet and Cancer Study. Baseline data included lifestyle factors including anthropometry, reproductive history, and exogenous hormone use. During follow-up (mean: 12.8 years), 747 invasive breast cancers were diagnosed. Expression of AR was determined by immunohistochemistry in tumor tissue microarrays.
RESULTS: AR status was assessable in 516 of 747 tumors (69%). Among these, 467 tumors (90.5%) were AR positive (AR(+)) and 49 tumors (9.5%) were AR negative (AR(-)). AR negativity was significantly associated with estrogen receptor (ER) and progesterone receptor negativity, higher grade and proliferation (Ki67). Cox regression analyses stratified by AR status showed significant associations between reproductive factors and AR(-) breast cancer. The older the woman at first childbirth the higher the risk of AR(-) breast cancer; adjusted HR≤20yrs = 0.35, HR>20-≤25yrs = 0.62, HRnulliparous = 1.00, HR>25-≤30yrs = 1.29, HR>30yrs = 1.92, p trend = 0.001. No such association was seen for AR(+) tumors. Similarly, ever oral contraceptive use increased the risk of AR(-) breast cancer [Adj. HR = 2.59, 95% CI (1.26-5.34)] compared to never use, but not for AR(+) breast cancer.
CONCLUSIONS: Advanced age at first child birth and use of oral contraceptives were associated with increased risk of AR(-) breast cancer. This study may contribute to enhanced understanding of the role of the AR in breast carcinogenesis and improve risk stratification tools for personalized breast cancer prevention.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24825327     DOI: 10.1007/s10552-014-0394-2

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  12 in total

1.  The Impact of Hormonal Contraceptives on Breast Cancer Pathology.

Authors:  Jesse A Dorchak; Sifat Maria; Joseph L Guarinoni; Anette Duensing; Stella Somiari; Jane Cavanaugh; Brenda Deyarmin; Hai Hu; Joji Iida; Craig D Shriver; Paula A Witt-Enderby
Journal:  Horm Cancer       Date:  2018-04-23       Impact factor: 3.869

2.  Zinc and Breast Cancer Survival: A Prospective Cohort Study of Dietary Intake and Serum Levels.

Authors:  Ylva Bengtsson; Kamil Demircan; Ann H Rosendahl; Signe Borgquist; Malte Sandsveden; Jonas Manjer
Journal:  Nutrients       Date:  2022-06-22       Impact factor: 6.706

Review 3.  Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures.

Authors:  Olga Golubnitschaja; Manuel Debald; Kristina Yeghiazaryan; Walther Kuhn; Martin Pešta; Vincenzo Costigliola; Godfrey Grech
Journal:  Tumour Biol       Date:  2016-07-22

4.  MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome.

Authors:  Imen Medimegh; Ines Omrane; Maud Privat; Nancy Uhrhummer; Hajer Ayari; Fadoua Belaiba; Farhat Benayed; Khaled Benromdhan; Sylvie Mader; Ives-Jean Bignon; Amel Benammar Elgaaied
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

5.  Mammographic tumour appearance is related to clinicopathological factors and surrogate molecular breast cancer subtype.

Authors:  Li Sturesdotter; Malte Sandsveden; Kristin Johnson; Anna-Maria Larsson; Sophia Zackrisson; Hanna Sartor
Journal:  Sci Rep       Date:  2020-11-30       Impact factor: 4.379

6.  The association of subtypes of breast cancer with tumour characteristics and reproductive factors in 1326 Mexican women.

Authors:  Gabriel Pérez-Rodríguez; Catalina Aranda-Moreno; Ivonne M Olivares-Corichi; Jose R Garcia-Sanchez
Journal:  Contemp Oncol (Pozn)       Date:  2016-01-13

7.  Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer.

Authors:  Erik Hilborn; Jelena Gacic; Tommy Fornander; Bo Nordenskjöld; Olle Stål; Agneta Jansson
Journal:  Br J Cancer       Date:  2016-01-07       Impact factor: 7.640

8.  Androgen receptor expression in normal breast tissue and subsequent breast cancer risk.

Authors:  Kevin H Kensler; Francisco Beca; Gabrielle M Baker; Yujing J Heng; Andrew H Beck; Stuart J Schnitt; Aditi Hazra; Bernard A Rosner; A Heather Eliassen; Susan E Hankinson; Myles Brown; Rulla M Tamimi
Journal:  NPJ Breast Cancer       Date:  2018-09-21

9.  Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.

Authors:  Elie Dagher; Violette Royer; Paul Buchet; Jérôme Abadie; Delphine Loussouarn; Mario Campone; Frédérique Nguyen
Journal:  BMC Cancer       Date:  2019-12-30       Impact factor: 4.430

10.  Serum zinc and dietary intake of zinc in relation to risk of different breast cancer subgroups and serum levels as a marker of intake: a prospective nested case-control study.

Authors:  Ylva Bengtsson; Malte Sandsveden; Signe Borgquist; Jonas Manjer
Journal:  Breast Cancer Res Treat       Date:  2021-07-05       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.